This purposeful conversation among the serotoninergic and central dopaminergic units has actually been shown in experiments with haloperidol, a D2 receptor antagonist that attenuates the psychotomimetic consequences of psilocybin [five]. Fortunately, in recent years the prospective benefits of ps